小林和史

研究者氏名	小林和史
	コバヤシカズフミ
URL
所属	千葉大学
部署	大学院医学研究院　消化器内科学
職名
学位	医学博士(千葉大学)
科研費研究者番号	40836615
J-Global ID	202101015962864350

論文

12 3 4 5 >

A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma and high tumor burden: The LAUNCH study.

Kazufumi Kobayashi Sadahisa Ogasawara Susumu Maruta Tomomi Okubo Norio Itokawa Yuki Haga Yuya Seko Michihisa Moriguchi Shunji Watanabe Yuki Shiko Hirokazu Takatsuka Hiroaki Kanzaki Keisuke Koroki Masanori Inoue Masato Nakamura Soichiro Kiyono Naoya Kanogawa Takayuki Kondo Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Yosuke Inaba Masafumi Ikeda Shinichiro Okabe Naoki Morimoto Yoshito Itoh Kazuyoshi Nakamura Kenji Ito Ryosaku Azemoto Masanori Atsukawa Ei Itobayashi Naoya Kato

Clinical cancer research : an official journal of the American Association for Cancer Research 2023年10月

BACKGROUND AND AIMS: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from the REFLECT trial. METHODS: This multicenter, nonrandomized, open-label prospective study was condu...

Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury.

Takayuki Kondo Kentaro Fujimoto Kisako Fujiwara Sae Yumita Takamasa Ishino Keita Ogawa Miyuki Nakagawa Terunao Iwanaga Keisuke Koroki Hiroaki Kanzaki Masanori Inoue Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Sadahisa Ogasawara Shingo Nakamoto Tetsuhiro Chiba Jun Kato Keiichi Fujiwara Naoya Kato

Scientific reports 13(1) 14043-14043 2023年8月

The pathogenesis of acute liver failure (ALF) involves cell death. Necroptosis is a newly suggested programmed cell death, and receptor-interacting protein kinase 3 (RIPK3) has been reported as a marker for necroptosis. However, there are few repo...

Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.

Hiroaki Kanzaki Sadahisa Ogasawara Tomomi Okubo Norio Itokawa Ryohei Yoshino Kentaro Fujimoto Tadayoshi Kogure Sae Yumita Takamasa Ishino Keita Ogawa Terunao Iwanaga Miyuki Nakagawa Kisako Fujiwara Ryuta Kojima Keisuke Koroki Masanori Inoue Kazufumi Kobayashi Naoya Kanogawa Soichiro Kiyono Masato Nakamura Takayuki Kondo Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Ei Itobayashi Masanori Atsukawa Jun Kato Naoya Kato

Drugs - real world outcomes 2023年7月

BACKGROUND: Cabozantinib was found to be effective as a second- or third-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) in the phase 3 CELESTIAL trial. So far, as immunotherapy has substituted molecular tar...

Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients.

Takayuki Kondo Kisako Fujiwara Miyuki Nakagawa Kentaro Fujimoto Sae Yumita Takamasa Ishino Keita Ogawa Terunao Iwanaga Keisuke Koroki Hiroaki Kanzaki Masanori Inoue Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Sadahisa Ogasawara Shingo Nakamoto Tetsuhiro Chiba Jun Kato Naoya Kato

Scientific reports 13(1) 11524-11524 2023年7月

The effect of the combination of atezolizumab and bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC) on pulmonary arterial hypertension (PAH) is unknown. Estimation of PAH by using computed tomography (CT) has recently been proposed. Thus, ...

薬物療法全盛時代における進行肝細胞癌に対する動注化学療法のリポジショニング

渡部主樹小林和史小笠原定久藤本健太郎石野貴雅小川慶太弓田冴岩永光巨中川美由貴藤原希彩子神崎洋彰興梠慧輔井上将法中村昌人叶川直哉清野宗一郎近藤孝行中本晋吾千葉哲博加藤直也

肝臓 64(Suppl.1) A465-A465 2023年4月